Stocks Listing
CYTK

Cytokinetics, Incorporated

Share
CYTK
$40.68 0.42%Last Updated Nov 25 2022 08:56 PM
1D Low / 1D High
Low:$40.00
High:$40.99
1D
0.42%
5D
0.79 %
30D
8.05 %
BulletPurple
Market Cap
$3,849,588,992
0.42 %
3.8 B
BulletBlue
Volume 1D
294,819
-
294.8 K
BulletOrange
Circulating Supply
94,630,998 CYTK
94.6 M

Price Chart

1D
5D
1M
6M
YTD
1Y
MAX
About

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Historical data

1D
5D
1M
6M
1Y
MAX
Day
Open - Close
Low/High
Volume
Market Cap
Show More
Market Status
Opened
NMS
NASDAQ Stock Exchange
USA
Closes in
5 hours, 26 minutes
Working Hours
Mon-Fri, 02:30 PM - 09:00 PM
Timezone
GMT+0